These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 37546576)

  • 1. Challenges and opportunities for incentivising antibiotic research and development in Europe.
    Anderson M; Panteli D; van Kessel R; Ljungqvist G; Colombo F; Mossialos E
    Lancet Reg Health Eur; 2023 Oct; 33():100705. PubMed ID: 37546576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategies to improve antibiotic access and a way forward for lower middle-income countries.
    Wasan H; Reeta KH; Gupta YK
    J Antimicrob Chemother; 2024 Jan; 79(1):1-10. PubMed ID: 38008421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incentivising innovation in antibiotic drug discovery and development: progress, challenges and next steps.
    Simpkin VL; Renwick MJ; Kelly R; Mossialos E
    J Antibiot (Tokyo); 2017 Dec; 70(12):1087-1096. PubMed ID: 29089600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Encouraging the Development of New Antibiotics: Are Financial Incentives the Right Way Forward? A Systematic Review and Case Study.
    Dutescu IA; Hillier SA
    Infect Drug Resist; 2021; 14():415-434. PubMed ID: 33574682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discrete choice experiment to investigate preferences for incentives to promote antimicrobial research and development.
    Rohde L; Mossialos E; Beaudart C; Joos A; Heikkinen I; Holland S; Hiligsmann M
    J Glob Antimicrob Resist; 2022 Jun; 29():42-48. PubMed ID: 35172202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimating The Appropriate Size Of Global Pull Incentives For Antibacterial Medicines.
    Outterson K
    Health Aff (Millwood); 2021 Nov; 40(11):1758-1765. PubMed ID: 34724432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Public funding for research on antibacterial resistance in the JPIAMR countries, the European Commission, and related European Union agencies: a systematic observational analysis.
    Kelly R; Zoubiane G; Walsh D; Ward R; Goossens H
    Lancet Infect Dis; 2016 Apr; 16(4):431-40. PubMed ID: 26708524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transferable Exclusivity Vouchers and Incentives for Antimicrobial Development in the European Union.
    Van de Wiele VL; Raymakers A; Kesselheim AS; Rome BN
    J Law Med Ethics; 2023; 51(1):213-216. PubMed ID: 37226746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Broken Antibiotic Market: Review of Strategies to Incentivize Drug Development.
    Bhavnani SM; Krause KM; Ambrose PG
    Open Forum Infect Dis; 2020 Jul; 7(7):ofaa083. PubMed ID: 32667365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systems, not pills: The options market for antibiotics seeks to rejuvenate the antibiotic pipeline.
    Brogan DM; Mossialos E
    Soc Sci Med; 2016 Feb; 151():167-72. PubMed ID: 26808335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Financing Pull Mechanisms for Antibiotic-Related Innovation: Opportunities for Europe.
    Årdal C; Lacotte Y; Ploy MC
    Clin Infect Dis; 2020 Nov; 71(8):1994-1999. PubMed ID: 32060511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-resistant tuberculosis in the European Union: opportunities and challenges for control.
    Fears R; Kaufmann S; Ter Meulen V; Zumla A;
    Tuberculosis (Edinb); 2010 May; 90(3):182-7. PubMed ID: 20382566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring the Obstacles to Implementing Economic Mechanisms to Stimulate Antibiotic Research and Development: A Multi-Actor and System-Level Analysis.
    Baraldi E; Ciabuschi F; Leach R; Morel CM; Waluszewski A
    Am J Law Med; 2016 May; 42(2-3):451-486. PubMed ID: 29086643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implementing an EU pull incentive for antimicrobial innovation and access: blueprint for action.
    Anderson M; Towse A; Outterson K; Mossialos E
    Lancet Microbe; 2024 Jun; ():. PubMed ID: 38885690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incentives for new antibiotics: the Options Market for Antibiotics (OMA) model.
    Brogan DM; Mossialos E
    Global Health; 2013 Nov; 9():58. PubMed ID: 24199835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Grant Framework as a Push Incentive to Stimulate Research and Development of New Antibiotics.
    Savic M; Årdal C
    J Law Med Ethics; 2018 Jun; 46(1_suppl):9-24. PubMed ID: 30146963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transferrable Market Exclusivity Extensions to Promote Antibiotic Development: An Economic Analysis.
    Rome BN; Kesselheim AS
    Clin Infect Dis; 2020 Oct; 71(7):1671-1675. PubMed ID: 31630159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Past, Present, and Future of Antibacterial Economics: Increasing Bacterial Resistance, Limited Antibiotic Pipeline, and Societal Implications.
    Luepke KH; Suda KJ; Boucher H; Russo RL; Bonney MW; Hunt TD; Mohr JF
    Pharmacotherapy; 2017 Jan; 37(1):71-84. PubMed ID: 27859453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New business models for antibiotic innovation.
    So AD; Shah TA
    Ups J Med Sci; 2014 May; 119(2):176-80. PubMed ID: 24646116
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.